Processes for making cyclic lipid implants for intraocular use
First Claim
Patent Images
1. A solid intraocular implant comprising a cyclic lipid therapeutic agent, a polymer and a low melting cosolvent,wherein the solubility parameters of the cyclic lipid therapeutic agent, the polymer and the low melting cosolvent are all within about 10 MPa1/2 of each other;
- wherein the low melting cosolvent has a melt temperature of between about 50°
C. and about 80°
C.;
wherein the cyclic lipid therapeutic agent is selected from the group consisting of bimatoprost, latanoprost, travoprost, unoprostone, prostaglandin E1, prostaglandin E2, and mixtures thereof;
wherein the polymer is a biodegradable polymer selected from the group consisting of polylactic acid, polyglycolic acid, and polylactide-co-glycolide; and
wherein the low melting cosolvent is selected from the group consisting of decafluorobutane, poly(hexamethylene adipamide), and polyethylene glycol 3350;
wherein the cyclic lipid agent comprises 20% by weight of the intraocular implant,wherein the potency of the cyclic lipid therapeutic agent released from the implant is at least about 50% of its maximum potency; and
wherein no polymorphs of the therapeutic agent are present in the implant.
1 Assignment
0 Petitions
Accused Products
Abstract
Biocompatible implants comprising a cyclic lipid therapeutic agent are made using a low temperature melt extrusion process. The implants are suitable for intraocular use to treat an ocular condition.
19 Citations
6 Claims
-
1. A solid intraocular implant comprising a cyclic lipid therapeutic agent, a polymer and a low melting cosolvent,
wherein the solubility parameters of the cyclic lipid therapeutic agent, the polymer and the low melting cosolvent are all within about 10 MPa1/2 of each other; -
wherein the low melting cosolvent has a melt temperature of between about 50°
C. and about 80°
C.;wherein the cyclic lipid therapeutic agent is selected from the group consisting of bimatoprost, latanoprost, travoprost, unoprostone, prostaglandin E1, prostaglandin E2, and mixtures thereof; wherein the polymer is a biodegradable polymer selected from the group consisting of polylactic acid, polyglycolic acid, and polylactide-co-glycolide; and wherein the low melting cosolvent is selected from the group consisting of decafluorobutane, poly(hexamethylene adipamide), and polyethylene glycol 3350; wherein the cyclic lipid agent comprises 20% by weight of the intraocular implant, wherein the potency of the cyclic lipid therapeutic agent released from the implant is at least about 50% of its maximum potency; and wherein no polymorphs of the therapeutic agent are present in the implant. - View Dependent Claims (2, 3, 4, 5, 6)
-
Specification